American Century Companies’s Rapport Therapeutics RAPP Stock Holding History

American Century Companies’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.74M	Buy	65,764 +9,472	+17%	+$348K	﹤0.01%	2103
2026 Q1	$1.76M	Buy	56,292 +9,443	+20%	+$266K	﹤0.01%	2171
2025 Q4	$1.42M	Buy	46,849 +28,599	+157%	+$791K	﹤0.01%	2212
2025 Q3	$542K	Buy	+18,250	New	+$326K	﹤0.01%	2489

Other funds holding RAPP

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

American Century Companies's RAPP Position: Q2 2026 in Review

American Century Companies increased its Rapport Therapeutics (RAPP) stake by 17% in Q2 2026, buying an estimated $348K and bringing the position to 65,764 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #2103.

American Century Companies first reported a position in RAPP in Q3 2025 and has held it in 4 quarters since. 146 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

American Century Companies held 65,764 shares of Rapport Therapeutics worth $2.74M as of Q2 2026.
American Century Companies bought 9,472 Rapport Therapeutics shares in Q2 2026, an estimated $348K.
Rapport Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2103 holding.
American Century Companies first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 4 quarters since.
146 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.